These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11999622)

  • 1. The Hospital for Sick Children, Toronto, Longitudinal ERG study of children on vigabatrin.
    Westall CA; Logan WJ; Smith K; Buncic JR; Panton CM; Abdolell M
    Doc Ophthalmol; 2002 Mar; 104(2):133-49. PubMed ID: 11999622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the electroretinogram resulting from discontinuation of vigabatrin in children.
    Westall CA; Nobile R; Morong S; Buncic JR; Logan WJ; Panton CM
    Doc Ophthalmol; 2003 Nov; 107(3):299-309. PubMed ID: 14711162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in photopic OPs occurring with vigabatrin treatment.
    Morong S; Westall CA; Nobile R; Buncic JR; Logan WJ; Panton CM; Abdolell M
    Doc Ophthalmol; 2003 Nov; 107(3):289-97. PubMed ID: 14711161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the ERG d-wave with vigabatrin treatment in a pediatric cohort.
    Dragas R; Westall C; Wright T
    Doc Ophthalmol; 2014 Oct; 129(2):97-104. PubMed ID: 25008578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vigabatrin and retinal changes.
    Jensen H; Sjö O; Uldall P; Gram L
    Doc Ophthalmol; 2002 Mar; 104(2):171-80. PubMed ID: 11999624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin effect on inner retinal function.
    Coupland SG; Zackon DH; Leonard BC; Ross TM
    Ophthalmology; 2001 Aug; 108(8):1493-6; discussion 1497-8. PubMed ID: 11470707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of vigabatrin on electrophysiology and visual fields in epileptics: a controlled study with a discussion of possible mechanisms.
    Comaish IF; Gorman C; Brimlow GM; Barber C; Orr GM; Galloway NR
    Doc Ophthalmol; 2002 Mar; 104(2):195-212. PubMed ID: 11999627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hand-held, dilation-free, electroretinography in children under 3 years of age treated with vigabatrin.
    Ji X; McFarlane M; Liu H; Dupuis A; Westall CA
    Doc Ophthalmol; 2019 Jun; 138(3):195-203. PubMed ID: 30826910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.
    Westall CA; Wright T; Cortese F; Kumarappah A; Snead OC; Buncic JR
    Neurology; 2014 Dec; 83(24):2262-8. PubMed ID: 25381295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visual field constriction and electrophysiological changes associated with vigabatrin.
    Besch D; Kurtenbach A; Apfelstedt-Sylla E; Sadowski B; Dennig D; Asenbauer C; Zrenner E; Schiefer U
    Doc Ophthalmol; 2002 Mar; 104(2):151-70. PubMed ID: 11999623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiological evaluation of retinal function in children receiving vigabatrin medication.
    Kjellström U; Andréasson S; Ponjavic V
    J Pediatr Ophthalmol Strabismus; 2011; 48(6):357-65. PubMed ID: 21261244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
    Kjellström U; Lövestam-Adrian M; Andréasson S; Ponjavic V
    Doc Ophthalmol; 2008 Sep; 117(2):93-101. PubMed ID: 18188629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual field and electrophysiological abnormalities due to vigabatrin.
    van der Torren K; Graniewski-Wijnands HS; Polak BC
    Doc Ophthalmol; 2002 Mar; 104(2):181-8. PubMed ID: 11999625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristic retinal atrophy with secondary "inverse" optic atrophy identifies vigabatrin toxicity in children.
    Buncic JR; Westall CA; Panton CM; Munn JR; MacKeen LD; Logan WJ
    Ophthalmology; 2004 Oct; 111(10):1935-42. PubMed ID: 15465561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electro-ophthalmological recovery after withdrawal from vigabatrin.
    Graniewski-Wijnands HS; van der Torren K
    Doc Ophthalmol; 2002 Mar; 104(2):189-94. PubMed ID: 11999626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroretinographic (ERG) responses in pediatric patients using vigabatrin.
    Moskowitz A; Hansen RM; Eklund SE; Fulton AB
    Doc Ophthalmol; 2012 Jun; 124(3):197-209. PubMed ID: 22426576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Field-specific visual-evoked potentials: identifying field defects in vigabatrin-treated children.
    Harding GF; Spencer EL; Wild JM; Conway M; Bohn RL
    Neurology; 2002 Apr; 58(8):1261-5. PubMed ID: 11971096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of the retinal nerve fibre layer and reduced retinal function assessed by optical coherence tomography and full-field electroretinography in patients exposed to vigabatrin medication.
    Kjellström U; Andréasson S; Ponjavic V
    Acta Ophthalmol; 2014 Mar; 92(2):149-57. PubMed ID: 23387307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological Evidences of Visual Field Alterations in Children Exposed to Vigabatrin Early in Life.
    Hébert-Lalonde N; Carmant L; Major P; Roy MS; Lassonde M; Saint-Amour D
    Pediatr Neurol; 2016 Jun; 59():47-53. PubMed ID: 27105764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual field defects associated with vigabatrin therapy.
    Lawden MC; Eke T; Degg C; Harding GF; Wild JM
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):716-22. PubMed ID: 10567485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.